For decades, most African nations have relied heavily on imported medications to meet their populations’ healthcare needs. In this analysis, pharmacist and engineer Dr. Arnaud Kaboré outlines a strategic roadmap for public leaders to achieve pharmaceutical self-sufficiency by 2045.

Why pharmaceutical dependence threatens Africa’s health security

Despite progress, fewer than five African countries currently operate export-oriented pharmaceutical manufacturing facilities. This leaves the continent importing 94% of its medicines at an annual cost exceeding $18 billion—a figure projected to surpass $30 billion by 2030. While the economic impact is severe, the deeper concern lies in the structural vulnerability this dependence creates.

According to recent assessments, over 70% of public health facilities across Africa experience critical medicine shortages at least once per quarter. Is it sustainable that the health of 1.4 billion Africans should hinge entirely on industrial, logistical, and geopolitical decisions made beyond the continent’s borders? The Covid-19 pandemic exposed these risks when essential drugs like amoxicillin, insulin, and anesthetics became scarce. Chronic shortages of cancer treatments and innovative therapies have led to untreated illnesses, price surges during shortages, and crippled public health programs. Yet Africa possesses untapped potential:

• A rapidly expanding market: Africa’s pharmaceutical sector could exceed $70 billion by 2030.
• Rich medicinal biodiversity: Over 5,400 documented medicinal plants, several already integrated into official therapeutic protocols.
• Regulatory momentum: The African Medicines Agency (AMA), ratified by 27 countries, is standardizing pharmaceutical regulations.
• Political commitment: Countries like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa have launched ambitious local production initiatives.

Building a sustainable African pharmaceutical industry

One critical misstep has been attempting to replicate the models of multinational pharmaceutical corporations without establishing the foundational elements of their value chains. Industrialization cannot be achieved by importing equipment alone—it requires parallel investments in human capital, technical expertise, and domestic industrial assets. Otherwise, local production becomes more expensive than imports, perpetuating dependence on foreign raw materials, technology, and expertise.

True pharmaceutical independence demands rigorous, long-term planning tailored to Africa’s unique context. Success hinges on leveraging the continent’s strengths: a growing market, medicinal biodiversity, regulatory progress, and political will. This analysis presents a pragmatic roadmap for policymakers to reclaim Africa’s pharmaceutical sovereignty by 2045. The goal is clear: produce locally to heal locally, and one day, heal the world.

Dr. Arnaud Kaboré
Pharmacist and Health Sector Executive